Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

Until recently, racemic ketamine (S-ketamine/R-ketamine = 50:50) has been used to study NMDA receptor hypofunction in relation to pathophysiological models of schizophrenia. Ketamine given to normal humans in subanesthetic doses produces a model psychosis including both positive and negative symptoms of schizophrenia. More recently it has been shown that at subanesthetic doses the pure (S)- and (R)-ketamine enantiomeres interact differently with the NMDA and sigma receptor sites in human brain. It was found that (S)-ketamine binds with a 3-4 time higher affinity to the PCP binding site of the NMDA receptor than (R)-ketamine, and that at these concentrations (R)-ketamine interacts also weakly with the sigma receptor sites, where (S)-ketamine binds only negligibly. To further investigate the role of NMDA-receptor mediated neurotransmission in schizophrenic psychosis, the effects of pure (S)- and (R)-ketamine enantiomeres on brain energy metabolism in normal humans using positron emission tomography and [18F]fluorodeoxyglucose (FDG) are reported here. Psychotomimetic doses of (S)-ketamine increased cerebral metabolic rates of glucose (CMRglu) markedly in the frontal cortex including the anterior cingulate, parietal and left sensorimotor cortex, and in the thalamus. The metabolic changes in the frontal and left temporal cortex correlated with ego-disintegration and hallucinatory phenomena. Equimolar doses of (R)-ketamine tended to decrease CMRglu across brain regions and significantly suppressed CMRglu in the temporomedial cortex and left insula. (R)-ketamine did not produce psychotic symptoms, but a state of relaxation. The (S)-ketamine-induced metabolic hyperfrontality appears to parallel similar metabolic findings in acute psychotic schizophrenic patients and encourages further investigations of glutamatergic disturbances in schizophrenia.

[1]  D. Lodge,et al.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.

[2]  E. Minder,et al.  Development of a Gas Chromatography‐Mass Spectrometry Method for Determination of Ketamine in Plasma and Its Application to Human Samples , 1995, Therapeutic drug monitoring.

[3]  H. de Wit,et al.  Behavioral and subjective effects of ethanol: relationship to cerebral metabolism using PET. , 1990, Alcoholism, clinical and experimental research.

[4]  H. D. Mummendey Das Freiburger Persönlichkeitsinventar (FPI) von J. Fahrenberg und H. Selg , 1971 .

[5]  A Carlsson,et al.  Schizophrenia: a subcortical neurotransmitter imbalance syndrome? , 1990, Schizophrenia bulletin.

[6]  Karl J. Friston,et al.  Patterns of Cerebral Blood Flow in Schizophrenia , 1992, British Journal of Psychiatry.

[7]  P. Slater,et al.  Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.

[8]  Barbara B. Collier,et al.  Ketamine and the conscious mind , 1972, Anaesthesia.

[9]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[10]  H. Meltzer,et al.  Phencyclidine as an indirect dopamine agonist [proceedings]. , 1980, Psychopharmacology bulletin.

[11]  E. Domino,et al.  NMDA receptor related agents : biochemistry, pharmacology and behavior , 1991 .

[12]  T Jones,et al.  In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas , 1983, Annals of neurology.

[13]  J. Chapman The Early Symptoms of Schizophrenia , 1966, British Journal of Psychiatry.

[14]  P. Contreras,et al.  PCP‐induced alterations in cerebral glucose utilization in rat brain: Blockade by metaphit, a PCP‐receptor‐acylating agent , 1987, Synapse.

[15]  I. Øye,et al.  Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain , 1995, Pain.

[16]  E. Domino,et al.  Sigma and Phencyclidine: Like Compounds As Molecular Probes in Biology , 1988 .

[17]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[18]  E. Domino,et al.  Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man , 1965, Clinical pharmacology and therapeutics.

[19]  A. Weber,et al.  The syndrome concept: history and statistical operationalizations , 1984, Psychological Medicine.

[20]  E. Domino PCP (phencyclidine), historical and current perspectives , 1981 .

[21]  O. Paulsen,et al.  Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[22]  N. Volkow,et al.  Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[23]  Karl J. Friston,et al.  Localisation in PET Images: Direct Fitting of the Intercommissural (AC—PC) Line , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  M. Spitzer,et al.  Beziehungen der Modell- bzw. Drogenpsychosen zu schizophrenen Erkrankungen , 1992 .

[25]  C. Scharfetter Ego-psychopathology: the concept and its empirical evaluation , 1981, Psychological Medicine.

[26]  M. Toru,et al.  Increases in strychnine-insensiive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis , 1994, Biological Psychiatry.

[27]  R. Waziri,et al.  Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics , 1991, Biological Psychiatry.

[28]  M S Buchsbaum,et al.  Glucose Metabolic Rate in Normals and Schizophrenics During the Continuous Performance Test Assessed by Positron Emission Tomography , 1990, British Journal of Psychiatry.

[29]  H. Sass,et al.  [Psychedelic experiences at the onset of productive episodes of endogenous psychoses]. , 1994, Der Nervenarzt.

[30]  F. Vollenweider,et al.  Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.

[31]  Klaus P. Ebmeier,et al.  Single-photon emission computed tomography with 99mTc-exametazime in unmediated schizophrenic patients , 1993, Biological Psychiatry.

[32]  F. Vollenweider,et al.  Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) , 1997, European Neuropsychopharmacology.

[33]  C. Scharfetter Paranoid-halluzinatorische Zustandsbilder bei drogeninduzierten Psychosen , 1987 .

[34]  Karl J. Friston,et al.  Plastic transformation of PET images. , 1991, Journal of computer assisted tomography.

[35]  G. Debonnel Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. , 1993, Journal of psychiatry & neuroscience : JPN.

[36]  S. Nelson,et al.  Ketamine-induced changes in regional glucose utilization in the rat brain. , 1980, Anesthesiology.

[37]  C. Nahmias,et al.  Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia , 1989, Psychiatry Research.

[38]  O. Paulsen,et al.  The chiral forms of ketamine as probes for NMDA receptor functions in humans , 1991 .

[39]  T. Hilden,et al.  The psychotropic effect of ketamine. , 1988, Journal of psychoactive drugs.

[40]  E. Domino,et al.  Changing Concepts in Pain Control During Surgery: Dissociative Anesthesia With CI‐581 A Progress Report , 1968, Anesthesia and analgesia.

[41]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[42]  Claude Nahmias,et al.  Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by position emission tomography (PET) , 1993, Schizophrenia Research.

[43]  M. Herkenham,et al.  Correlation of regional brain metabolism with receptor localization during ketamine anesthesia: combined autoradiographic 2-[3H]deoxy-D-glucose receptor binding technique. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Bowers,et al.  "Psychedelic" experiences in acute psychoses. , 1966, Archives of general psychiatry.

[45]  H. de Wit,et al.  Effects of ethanol, diazepam and amphetamines on cerebral metabolic rate: PET studies using FDG. , 1990, NIDA research monograph.

[46]  J. Hedreen,et al.  Sigma receptors in post-mortem human brains. , 1988, The Journal of pharmacology and experimental therapeutics.

[47]  A. Catafau,et al.  Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study , 1994, Psychiatry Research: Neuroimaging.

[48]  L. J. Chapman,et al.  Early subjective experience in schizophrenic episodes. , 1973, Journal of abnormal psychology.

[49]  R. Cadoret,et al.  Symptom differences in schizophrenia with good and poor prognosis. , 1972, The American journal of psychiatry.

[50]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[51]  J. Deakin,et al.  Alterations in phencyclidine and sigma binding sites in schizophrenic brains Effects of disease process and neuroleptic medication , 1991, Schizophrenia Research.

[52]  D. Swandulla,et al.  Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. , 1992, European journal of pharmacology.

[53]  M. Torrens Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[54]  James V. Hinrichs,et al.  Ketamine: behavioral effects of subanesthetic doses. , 1984, Journal of clinical psychopharmacology.

[55]  M. Piercey,et al.  Dramatic limbic and cortical effects mediated by high affinity PCP receptors. , 1988, Life sciences.